Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 17c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.67), $0.17 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49